Merck & Co. is the best overall pharmaceutical company for service to long-term care, according to nursing home executives.
Merck & Co. is the best overall pharmaceutical company for service to long-term care, according to nursing home executives surveyed in Scott-Levin's most recent Nursing Home Pharmacy Provider/Consultant promotional audit.
Scott-Levin auditors asked pharmacy providers and consultants who represent 63% of all nursing home beds in the United States to rank pharmaceutical companies on contracts, value-added services, knowledgeable sales reps and overall quality of service. Merck was rated above its competitors in all four categories.
Ironically, Merck ranked second in the number of contacts made with long-term care customers; Pfizer was first in the respect.
"Merck is taking some financial burden off us through continuing education programs, research, disease state management, studies, etc.," wrote one pharmacy provider who responded to the survey. Others who responded to the survey noted that Merck is "far superior in support," possesses a "great understanding of the long-term care industry" and has "great contracts, disease state management programs and educational programs."
Johnson & Johnson, Bayer, Pfizer and Novartis filled out the other top five spots in the overall quality category.
According to Scott-Levin's analysts, Johnson & Johnson's success may have been the result of increased promotional contacts made by ElderCare, the new long-term care group of its subsidiary, Janssen. ElderCare reps promoted Duragesic and Risperdal to long-term care customers.
Another new sales force specifically targeting long-term care customers belonged to Abbott Laboratories. "The company's young long-term care sales force accounted for 43% of Abbott's total contacts to long-term care," analysts noted. Nearly 70% of promotional call activity was dedicated to value-added services, which helped boost Abbott into the top 10 rankings in that category. One survey respondent stated that Abbott "made a push to be in the long-term care market, [and its] presence is improving." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.